BMY - BRISTOL MYERS SQUIBB CO

62.33
1.110   1.781%

Share volume: 12,306,233
Last Updated: 03-04-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.72%

PREVIOUS CLOSE
CHG
CHG%
$61.22
1.11
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
71%
Profitability 73%
Dept financing 40%
Liquidity 59%
Performance 79%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.02%
1 Month
4.72%
3 Months
19.52%
6 Months
32.22%
1 Year
4.20%
2 Year
20.28%
Key data
Stock price
$62.33
P/E Ratio 
15.38
DAY RANGE
$61.47 - $62.58
EPS 
$3.47
52 WEEK RANGE
$42.52 - $63.33
52 WEEK CHANGE
$3.57
MARKET CAP 
108.526 B
YIELD 
4.65%
SHARES OUTSTANDING 
2.036 B
DIVIDEND
$0.63
EX-DIVIDEND DATE
04-02-2026
NEXT EARNINGS DATE
07-25-2025
BETA 
-0.11
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$14,284,411
AVERAGE 30 VOLUME 
$14,106,535
Company detail
CEO: Giovanni Caforio
Region: US
Website: bms.com
Employees: 34,300
IPO year: 1972
Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma.

Recent news